Clinical Trials Directory

Trials / Sponsors / Boston Pharmaceuticals

Boston Pharmaceuticals

Industry · 12 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis
Phase 22025-04-09
CompletedA Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH
Nonalcoholic Steatohepatitis (NASH)
Phase 22021-09-30
CompletedStudy to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test
Chronic Plaque Psoriasis
Phase 12020-01-06
CompletedStudy to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical App
Moderate to Severe Acne Vulgaris
Phase 12019-11-04
CompletedStudy to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerabil
Healthy Participants
Phase 12019-09-12
CompletedStudy to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea
Diarrhea-predominant Irritable Bowel Syndrome
Phase 22019-06-04
CompletedStudy to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration o
Psoriasis
Phase 12019-04-23
CompletedSafety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET)
Advanced Nonhaematologic Malignancies
Phase 12018-12-12
CompletedStudy to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug
Healthy Subjects
Phase 12018-03-21
CompletedStudy of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
Systemic Lupus Erythematosus
Phase 1 / Phase 22018-01-10
CompletedStudy of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies
Advanced Nonhaematologic Malignancies
Phase 12017-10-13
CompletedStudy to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects
Healthy Participants
Phase 12017-01-01